TABLE 3.
Pharmacokinetic parameters for nelfinavir and its metabolites in 10 HIV-positive patients receiving nelfinavir treatment at 750 mg TIDa
| Day | Drug | Cmax (μM) | Tmax (h) | AUC0–8 (μM · h) | Cmin (μM) |
|---|---|---|---|---|---|
| 1 | Nelfinavir | 5.04 ± 2.56 | 3.9 ± 1.7 | 23.2 ± 10.7 | |
| M1 | 0.24 ± 0.13 (0.05) | 5.7 ± 1.8 | 1.02 ± 0.54 (0.04) | ||
| M8 | 1.73 ± 1.62 (0.33) | 5.5 ± 1.6 | 6.62 ± 7.15 (0.27) | ||
| 28 | Nelfinavir | 4.96 ± 2.22 | 2.9 ± 1.0 | 24.5 ± 10.2 | 1.73 ± 1.05 |
| M1 | 0.19 ± 0.10 (0.04) | 3.4 ± 1.4 | 1.11 ± 0.65 (0.05) | 0.09 ± 0.07 (0.05) | |
| M8 | 1.96 ± 1.10 (0.43) | 3.4 ± 1.4 | 9.04 ± 4.87 (0.39) | 0.55 ± 0.37 (0.34) |
a
Data are presented as means and standard deviations. Statistical comparisons for all corresponding values on days 1 and 28 did not show any significance differences. Numbers in parentheses are the mean ratio of the concentration of a metabolite (M1 or M8) to that of nelfinavir, measured in the same patient.